中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

40 records (took 0.025 seconds)

    Pretreating cellulosic biomass
    31.
    发明申请
    Pretreating cellulosic biomass 审中-公开
    预处理纤维素生物质

    公开(公告)号：US20090288788A1

    公开(公告)日：2009-11-26

    申请号：US12154398

    申请日：2008-05-22

    Applicant: Trevor Percival Castor

    Inventor： Trevor Percival Castor

    IPC: D21C3/22 ,  D21F1/66

    CPC classification number: D21C1/10 ,  C12P2201/00 ,  D21C5/005 ,  D21C11/0007 ,  Y02P20/544

    Abstract: The present invention pertains to methods for pretreatment of cellulosic biomass for bioconversion into ethanol and other biofuels and wood-based chemicals, recycling of newsprint and other paper products, microfibrillation of cellulose for use as an additive in the food and cosmetic industries, manufacturing improved hardboard, and producing and improved “super” pulp while reducing chemical usage and spent liquor generation. In particular, the instant invention employs supercritical, critical or near critical fluids with and without polar cosolvents [critical fluid, SuperFluids or SFS] for the pretreatment of cellulosic biomass.

    Abstract translation: 本发明涉及用于生物转化成乙醇和其他生物燃料和木质化学品的纤维素生物质的预处理方法，新闻纸和其他纸制品的再循环，用于食品和化妆品行业中的添加剂的纤维素的微纤维化，制造改进的硬纸板 ，并生产和改进“超级”纸浆，同时减少化学品使用和废液生成。 特别地，本发明使用具有和不具有极性助溶剂（临界流体，超流体或SFS）的超临界，临界或近临界流体用于纤维素生物质的预处理。

    THERMAL CONVERSION OF CBDA AND OTHER CARBOXYLIC CANNABINOIDS
    32.
    发明申请
    THERMAL CONVERSION OF CBDA AND OTHER CARBOXYLIC CANNABINOIDS 有权

    公开(公告)号：US20220340538A1

    公开(公告)日：2022-10-27

    申请号：US17727788

    申请日：2022-04-24

    Applicant: Trevor Percival Castor

    Inventor： Trevor Percival Castor

    IPC: C07D311/80 ,  C07C37/50 ,  C07C39/19 ,  C07C37/74 ,  B01J3/04

    Abstract: This invention is for improving the manufacturing pharmaceutical grade CBD and other cannabinoids following current Good Manufacturing Practices (cGMP) of the US FDA for use in clinical trials for CNS and other indications by the NIH and other researchers. The major cannabinoids in marijuana (Cannabis) and hemp originate from Cannabigerolic Acid (CBGA) present in the biomass of the plant. Plant enzymes that are specific to different strains of biomass converts CBGA to different carboxylic acids of cannabinoids including Cannabidiolic Acid (CBDA) and Δ9-Tetrahydrocannabinolic Acid (Δ9-THCA). These are relatively stable in the growing and fresh-cut plants. These are converted by thermal decarboxylation to Cannabidiol (CBD) and Δ9-Tetrahydrocannabinol (Δ9-THC), carbon dioxide and water. Cannabinoids can be manufactured by first heating the Cannabis biomass to convert carboxylic acids prior to extraction and purification. Alternatively, and preferably because of manufacturing cost and product stability, the carboxylic acids can be first extracted and purified. They can be utilized in the carboxylic acid form or stored in a stable manner until converted to cannabinoids for use in medicine. This invention provides an efficient method for their conversion utilizing a high-pressure reactor under inert conditions.

    ROOM TEMPERATURE STABLE, SINGLE SHOT mRNA VACCINE FOR COVID-19
    33.
    发明申请
    ROOM TEMPERATURE STABLE, SINGLE SHOT mRNA VACCINE FOR COVID-19 有权

    公开(公告)号：US20220296728A1

    公开(公告)日：2022-09-22

    申请号：US17699359

    申请日：2022-03-21

    Applicant: Trevor Percival Castor

    Inventor： Trevor Percival Castor

    IPC: A61K47/69 ,  A61K47/34 ,  A61P31/14 ,  A61K9/51

    Abstract: This disclosed technology relates to a new mRNA COVID-19 vaccine that is stable at room temperature, requires only one injection, and is less prone to patient hypersensitivity reactions. The vaccine is practical to deploy globally during vaccination campaigns for current and future coronavirus pandemics and other infectious diseases. The disclosed technology is a method and system for producing the vaccine, and also a double-encapsulated mRNA vaccine product. The method uses double nanoencapsulation of an mRNA vaccine, first in phospholipid nanosomes and then in biodegradable polymer nanospheres. The method may be carried out as a continuous flow, integral, or two-stage processes. The method and system use supercritical fluid technology for nanoencapsulating mRNA in a solvent free process that minimizes loss of potency and preserves antigenicity of the nanoencapsulated mRNA and eliminates residual organic solvents in the final product. The double-encapsulated mRNA vaccine product is stable at room temperature and can be administered in a single shot to humans.

    APPARATUS AND METHOD FOR INACTIVATIVING VIRUSES AND PATHOGENS IN CONVALESCENT PLASMA UNITS FROM RECOVERED COVID-19 PATIENTS
    36.
    发明申请
    APPARATUS AND METHOD FOR INACTIVATIVING VIRUSES AND PATHOGENS IN CONVALESCENT PLASMA UNITS FROM RECOVERED COVID-19 PATIENTS 有权

    公开(公告)号：US20220110972A1

    公开(公告)日：2022-04-14

    申请号：US17499792

    申请日：2021-10-12

    Applicant: Trevor Percival Castor

    Inventor： Trevor Percival Castor

    IPC: A61K35/16 ,  A61M1/38

    Abstract: The novel coronavirus COVID-19 has caused a worldwide pandemic of enormous proportions resulting in significant levels of morbidity and mortality, tremendous pressures on the healthcare system, personal freedoms and society, and an unprecedented impact on the economies of the United States and the world. There are still significant unknowns about this very contagious and deadly virus, and these unknowns are coupled with no natural immunity. A promising therapeutic strategy is the utilization/transfusion of convalescent plasma from recovered COVID-19 patients. There are, however, risks involved in such transfusions from residual virus and other adventitious viruses and bacteria. These risks can be minimized by the pathogen clearance of convalescent plasma units in a hospital setting. There is an immediate need for the rapid pathogen inactivation/clearance of convalescent plasma units from recovered COVID-19 patients.
    The present invention is a physical pathogen reduction and inactivation apparatus and method for controlling or eliminating transfusion-transmittable infections in convalescent plasma from recovered COVID-19 donors. The invention inactivates both nonenveloped and enveloped viruses as well as pathogenic bacteria and parasites in units of human plasma, while retaining the potency of natural biologically-active proteinaceous products in the pathogen-reduced plasma. The invention uses critical, near-critical or supercritical fluids for viral and pathogen reduction of units of donor blood plasma in blood bags. The apparatus is in the form of a transportable mobile unit, where it can be used in hospitals, blood banks, and medical facilities.

    Nanotechnology formulation of poorly soluble compounds
    38.
    发明授权
    Nanotechnology formulation of poorly soluble compounds 有权
    纳米技术配方的难溶性化合物

    公开(公告)号：US08703727B2

    公开(公告)日：2014-04-22

    申请号：US13216125

    申请日：2011-08-23

    Applicant: Trevor Percival Castor

    Inventor： Trevor Percival Castor

    IPC: A61K9/14

    CPC classification number: A61K31/133 ,  A61K9/4858 ,  A61K9/5153 ,  A61K9/5192 ,  A61K31/167 ,  A61K31/352 ,  A61K31/395 ,  A61K31/404 ,  B82Y5/00

    Abstract: Embodiments of the present invention are directed to articles of manufacture, spheres having a diameter of 50 to 500 nanometers which contain poorly soluble drugs and methods of making such spheres. Embodiments of the present invention have particular application for the following drug candidates and closely related poorly soluble derivatives of such candidates: (i) indole hydrazinecarbothioamide [NSC 73306]; (ii) fenretinide (4HPR) [NSC 374551]; (iii) safingol [NSC 714503]; (iv) 17-allylamino demethoxygeldanamycin (17-AAG) [NSC 330507]; and (v) an aminoflavone drug [NSC 686288].

    Abstract translation: 本发明的实施方案涉及制品，直径为50-500纳米的球体，其含有难溶性药物和制备这种球体的方法。 本发明的实施方案具体应用于以下药物候选物和这些候选物的密切相关的难溶性衍生物：（i）吲哚肼硫代硫酰胺[NSC 73306]; （ii）芬维A胺（4HPR）[NSC 374551]; （iii）safingol [NSC 714503]; （iv）17-烯丙基氨基去甲氧基格尔德霉素（17-AAG）[NSC 330507]; 和（v）氨基黄酮药物[NSC 686288]。

    Method of fractionation of biologically-derived materials using critical fluids
    40.
    发明授权
    Method of fractionation of biologically-derived materials using critical fluids 有权
    使用临界流体分解生物衍生物质的方法

    公开(公告)号：US06569640B1

    公开(公告)日：2003-05-27

    申请号：US09170282

    申请日：1998-10-13

    Applicant: Trevor Percival Castor ,  Glenn Thomas Hong

    Inventor： Trevor Percival Castor ,  Glenn Thomas Hong

    IPC: C07G1700

    CPC classification number: C12N1/005 ,  C07D305/14 ,  Y02P20/544

    Abstract: Supercritical and near critical fluids are used to fractionate biomass materials such as microbial cells in two steps. In the first step, the biomass is exposed to elevated pressure supercritical or near critical fluid to bring about disruption of the biomass to liberate structural biomass constituents. In the second step, the disrupted biomass is subjected to a multiplicity of supercritical or near critical fluid extraction steps, with different solvation conditions used for each fraction. Thus, fractionation of the biomass to obtain one or more compounds is effected. Different solvation properties are obtained using different temperatures, pressures and/or modifier concentrations.

    Abstract translation: 超临界和近临界流体用于在两个步骤中分解生物质材料如微生物细胞。 在第一步中，生物质暴露于超临界或临界液体的高压下，导致生物质的破坏以释放结构生物量成分。 在第二步中，破坏的生物质经受多个超临界或近临界流体萃取步骤，每个馏分使用不同的溶剂化条件。 因此，实现生物质的分级以获得一种或多种化合物。 使用不同的温度，压力和/或调节剂浓度获得不同的溶剂化性质。

Patent Agency Ranking